Prognostic Value of GSTP1 Methylation in Prostate Cancer
Author Information
Author(s): Pidsley Ruth, Lam Dilys, Qu Wenjia, Stricker Phillip, Kench James G., Horvath Lisa G., Clark Susan J.
Primary Institution: Garvan Institute of Medical Research
Hypothesis
The study aims to determine the prognostic significance of GSTP1 promoter methylation in prostate cancer.
Conclusion
GSTP1 methylation levels are associated with disease prognosis in prostate cancer, but do not provide independent prognostic value beyond standard clinical features.
Supporting Evidence
- 97% of radical prostatectomy samples had detectable mGSTP1 levels.
- mGSTP1 levels were significantly associated with biochemical recurrence and metastatic relapse free survival.
- Multivariable models showed mGSTP1 did not add independent prognostic value beyond standard clinical features.
Takeaway
This study looks at a special marker in prostate cancer that can help doctors understand how serious the disease might be, but it doesn't always give extra information beyond what they already know.
Methodology
The study used whole genome bisulphite sequencing and a methylation-specific head-loop assay to analyze GSTP1 methylation levels in prostate cancer tissue samples.
Limitations
GSTP1 methylation did not add independent prognostic value beyond standard clinicopathological features.
Participant Demographics
Patients with ISUP Grade Group 2 or greater who underwent radical prostatectomy.
Statistical Information
P-Value
p=0.045 for biochemical recurrence, p=0.021 for metastatic relapse, p=0.093 for prostate cancer specific mortality
Confidence Interval
HR=1.59 (1.01–2.51) for BCR, HR=2.54 (1.15–5.59) for MR
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website